Introduction
Inhibitory antibodies to factor VIII (fVIII) arise in response to infusions of fVIII in approximately 25% of previously untreated patients with hemophilia A 1, 2, 3, 4 . These antibodies increase the morbidity and mortality and cost of care in these patients. Treatment options include bypassing the requirement for factor VIII using activated coagulation factor concentrates or recombinant factor VIIa and the use of porcine fVIII 5 .
Additionally, inhibitory antibodies can be eliminated in some patients using immune tolerance induction regimens that include daily infusions of large doses of fVIII 6 . All of these treatment modalities are expensive and are not always successful.
A method to reduce the incidence of inhibitory antibody development would represent an improvement in the management of patients with hemophilia A. One possible strategy is to alter the factor VIII molecule and render it less immunogenic. The incidence of inhibitory antibody development is higher in patients with severe hemophilia A, presumably because they recognize factor VIII as immunologically Thus, mutagenesis of B cell epitopes without disruption of biological function is a strategy to reduce the incidence of inhibitor development in patients with hemophilia A.
Factor VIII contains a sequence of domains designated A1-A2-B-ap-A3-C1-C2 7 . The B domain can be deleted without loss of biological activity 8, 9 and B domain -deleted fVIII is effective in the treatment of hemophilia A 3 . Most of the inhibitory antibody activity is directed against epitopes in the A2 or C2 domains 10-14 15-17 . The A2 epitope has been localized to a single, continuous sequence bounded by residues R484-I508
15
. Antigenic residues within this segment that are recognized by human inhibitory antibodies include R484, Y487, S488, R489, P492, V495, F501, and I508
18
. Single alanine mutations at any of these sites results in the expression of functional fVIII molecules 18 . In the current study, we prepared B domaindeleted (BDD) human fVIII molecules containing mutations at R484A/R489A or R484A/R489A/P492A and compared the immunogenicity of these molecules to non-mutated human fVIII in hemophilia A mice.
only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From contain PACE/furin recognition linker sequences, were prepared as described previously 22, 24 . The cDNA for a BDD hybrid human/porcine fVIII molecule designated HP9, which contains insertion of the porcine segment corresponding to residues 484 -508 in the A2 domain of human fVIII (Figure 1 ), has been described previously 15 . A BDD hybrid human/murine fVIII cDNA, HM1, encoding a fVIII molecule that is murine except for a human segment corresponding to residues 484 -508 of the A2 domain (Figure 1 ), was constructed by splicing-by-overlap extension mutagenesis using MSQ as the template.
The construction of a cDNA encoding BDD R489A human fVIII has been described previously 18 and was modified further by insertion of DNA encoding the S F S Q N P P V L K R H Q R linker sequence. The resulting cDNA was used as a template for the production of cDNAs encoding R484A/R489A and R484A/R489A/P492A BDD human fVIII by splicing-by-overlap extension mutagenesis ( Figure 1 ). For the R484A/R489A mutant, 5'-CAC GGA ATC ACT GAT GTC GCC CCT TTG TAT TCA GCC AGA -3' and 5'-TCT GGC TGA ATA CAA AGG GGC GAC ATC AGT GAT TCC GTG -3' were used as the mutagenic sense and antisense primers, respectively. For the R484A/R489A/P492A mutant, 5 '-ACT GAT GTC GCC CCT   TTG TAT TCA GCC AGA TTA GCC AAA -3' and 5'-TTT GGC TAA TCT GGC TGA ATA CAA AGG GGC GAC ATC AGT -3' were used as the mutagenic sense and antisense primers, respectively.
Expression and purification of recombinant fVIII molecules
Recombinant fVIII molecules were expressed in baby hamster kidney -derived cells in serum-free medium using the ReNeo expression vector as described previously 25 . HSQ, HSQ R484A/R489A, HSQ R484A/R489A/P492A, MSQ, POL, HM1 were purified by SP-Sepharose Fast Flow and Source Q or Mono Q ion-exchange chromatography essentially as described previously for HSQ, MSQ and POL 22, 24 . HP9 was purified using the following procedure. Ammonium sulfate was added to 5.9 liters of cell culture medium at 4
°C to 65% saturation and allowed to stir overnight. The precipitate was collected by centrifugation, dialyzed against 0.15 M NaCl, 0.02 M Hepes, 5 mM CaCl 2 , 0.01% Tween-80, pH 7.4,and applied to a 1.5 x 10 cm ESH5 -Sepharose column equilibrated in the same buffer. HP9 was eluted with 1 M NaCl, 5 mM Mes, 2.5 mM CaCl 2 , 50% ethylene glycol (v/v), pH 6.0. Fractions from the fVIII activity peak were diluted 1/5 into 0.04 only.
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Purified proteins were at least 90% pure as judged by sodium dodecyl sulfate -polyacrylamide gel electrophoresis and contained heterodimeric fVIII as the dominant species. Concentrations were calculated using the absorbance at 280 nm of the purified proteins and molar extinction coefficients that were estimated from the respective deduced amino acid compositions 26 . The specific activities of the purified proteins were calculated using the protein concentration and fVIII coagulant activity, which was measured as described below against a human fVIII plasma standard. The following specific activities were obtained:
HSQ, 1300 U/nmole; HSQ R484A/R489A/P492A, 1270 U/nmole; HSQ R484A/R489A, 1460 U/nmol; HP9 1100, U/nmol; HM1 540, U/nmol. The specific activities of the POL and MSQ preparations have been previously reported as 2050 U/nmol and 660 U/nmol, respectively 22, 24 . Specific activities were converted to U/mg using a molecular weight of 165,000 for all fVIII species used in the study. Samples were diluted to 4 µg/ml in sterile normal saline immediately prior to injection. Eighty-three hemophilia A mice were divided into HSQ (n = 24), HSQ R484A/R489A/P492A (n = 23), HSQ R484A/R489A (n = 24), buffer injected control (n = 5) and non-injected control (n = 7) groups. Mice were warmed under a 75-watt lamp for 3 to 4 minutes to dilate tail veins before injection. Silver nitrate was used to cauterize bleeding after injections and tail snips. Recipients of different test materials were mixed within each cage and remained in their original cages to avoid fighting. Approximately equal numbers of males and females were in each group. Mice received six injections of 10 µg/kg body weight (~80 U/kg) at 14 day intervals, followed by a final injection of 25 µg/kg body weight (~ 200 U/kg) two weeks after the sixth dose.
Blood was collected by tail snip into 1/10 volume 3.8% trisodium citrate under metofane anesthesia 13 days only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From after the fourth injection and by terminal cardiac puncture 13-14 days after the final injection. Samples were held on ice prior to centrifugation at 3000 x g for 15 minutes at 4° C to collect plasma. During the course of the experiment 0, 4, 5, 1, and 2 mice died in the HSQ, HSQ R484A/R489A/P492A, HSQ R484A/R489A, buffer injected control and non-injected control groups, respectively. The overall mortality during the study was 14%, which is consistent with the increased mortality of hemophilia A mice associated with handling 20 .
In vivo clearance of HSQ and HSQ R484A/R489A/P492A HSQ or HSQ R484A/R489A/P492A were diluted to 50 U/ml (~ 6.25 µg/ml) in sterile saline for injection immediately before use. Hemophilia A mice were anesthetized with metofane, weighed, warmed under a 75-watt lamp for 3 minutes to dilate veins and injected with 100 U/kg (~ 12.5 µg/kg) by tail vein. Silver nitrate was used to cauterize the injection site. Because serial sampling from hemophilia A mice is difficult, three mice were used for each time point for each fVIII construct. At 0.25, 0.5, 1, 2, 4, 8, or 24 h, mice were anesthetized by intraperitoneal injection of a mixture of 300 mg/kg ketamine and 75 mg/kg xylazine and blood was collected by cardiac puncture into 1/10 volume of 3.8% trisodium citrate. Plasma samples were prepared by centrifugation and stored at -70°C. FVIII activity was determined by chromogenic assay as described below.
Hemostatic efficacy of HSQ and HSQ R484A/R489A/P492A
The hemostatic efficacy of HSQ R484A/R489A/P492A in hemophilia A mice was measured using a tail vein transection model as described previously 27 . Briefly, mice were anesthetized with 1.5 mg/kg droperidol/75 mg/kg ketamine intraperitoneally, warmed under a heat lamp to dilate the tail veins, and injected with HSQ R484A/R489A/P492A. After anesthesia was deepened using methoxyflurane, the distal 1 cm of tail was transected and the stump was placed in a test tube containing 150 mM NaCl at 37 °C. At 2 h, surviving mice only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From were caged and mortality at 24 h was determined. The up-and-down method for small samples 28, 29 was used to estimate the dose that produces 50% survival (ED 50 ). An initial dose of fVIII was given to a single mouse as an a priori estimate of the ED 50 . If the mouse survived the 24 h test period, another mouse was tested and the dose was decreased. If the subject died, the dose was increased in the next subject, etc., until a nominal sample size of six was reached. A constant log dose increment or decrement of 0.1, corresponding to a dilution factor of 1.26 was used. The ED 50 was calculated using the equation
Log ED 50 = x f + kd where x f is the logarithm of final test dose, d is the log dose increment or decrement, and k is obtained from a table based on maximum likelihood estimates 28 .
FVIII coagulation assays and ELISAs
FVIII activity was measured by one-stage clotting assay 30 as described previously 22 using normal human plasma (FACT) as the standard. FVIII inhibitor titers were measured by a modified Bethesda assay in which fVIII constructs (HSQ, HSQ R484A/R489A, HSQ R484A/R489A/P492A, HP9 or POL) were added to human hemophilia A plasma to a final concentration of 0.8 -1.2 units per ml and incubated with varying concentrations of inhibitor for 2 hours at 37 °C. One Bethesda unit (BU) is defined as the amount of inhibitory activity that produces 50% inhibition of fVIII activity in the one-stage clotting assay. The 50% inhibition point was identified by interpolation using only data points falling within a range of 40 -60%
inhibition. An average of at least three data points in this range were used for each determination. Because of the smaller volumes required, fVIII activity was measured in the pharmacokinetic study by a chromogenic assay (Coamatic, Chromogenix/Diapharma Group, West Chester, OH) according to instructions supplied by the manufacturer.
Antibodies to HSQ, HSQ R484A/R489A/P492A, MSQ, or HM1 were measured by ELISA using immobilized purified antigen bound to microtiter plates, followed by addition of dilutions of test plasma and only.
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Absorbance values obtained from seven dilutions of test plasma were plotted versus the logarithm of the plasma dilution and the resulting sigmoidal curves were fit to the 4-parameter logistic equation by nonlinear regression using the Levenberg-Marquardt algorithm. The ELISA titer was defined empirically as the dilution of plasma that returns an absorbance value of 0.3 derived from the fitted curves.
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Results

Immunodominance of human R484 -I508 epitope in hemophilia A mice
In an attempt to reduce the immunogenicity of human fVIII, two BDD fVIII mutants were developed that contain alanine substitutions of antigenic amino acids in the A2 domain. These, mutants, designated HSQ R484A/R489A and HSQ R484A/R489A/P492A (Figure 1) , were compared to a control BDD fVIII molecule (HSQ) in hemophilia A mice using an intravenous immunization protocol described in Materials and Methods. A critical question in this experimental model is whether hemophilia A mice recognize the R484 -I508 A2 sequence that is targeted by human anti-fVIII inhibitory antibodies. We used two approaches to address this problem. First, plasmas from the HSQ treatment group were tested for reactivity against a hybrid human/porcine fVIII molecule, designated HP9, which is human except for insertion of porcine sequence within the R484 -I508 segment (Figure 1 ). The rationale for this experiment is if immune plasmas contain antibodies that recognize the R484 -I508 epitope, they should react less well with the HP9 molecule than HSQ because of incomplete cross-reactivity of fVIII inhibitors with human and porcine fVIII.
The average Bethesda titers in the HSQ treatment group against HSQ and a BDD porcine fVIII construct designated POL were 680 and 31 Bethesda units, respectively, corresponding to a cross-reactivity of 4%, demonstrating that porcine fVIII is poorly cross-reactive in this model (data not shown). Figure 2A shows paired data comparing the inhibition of HSQ and HP9 by individual mouse plasmas in the Bethesda assay.
Bethesda titers of most of the pairs were decreased using HP9 as the target antigen compared to HSQ. The difference between the HP9 and HSQ groups was statistically significant (p < 0.0001, paired t test). Figure   2A also shows that all of the plasmas recognized HP9, indicating the presence of inhibitory epitopes directed toward human epitopes outside of the R484 -I508 A2 epitope.
The immunodominance of the human R484 -I508 segment in hemophilia A mice also was tested by a converse experiment in which the same plasmas were tested by ELISA for reactivity against a hybrid human/murine fVIII molecule, designated HM1, which is murine except for the human R484 -I508 segment (Figure 1 ). The average ELISA titer against BDD murine fVIII, MSQ, was 19% of that against HSQ (data not only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From shown), demonstrating that the plasmas cross-react poorly with murine fVIII, and thus that human/murine hybrid fVIII molecules can be used to study differential antigenicity. The HM1 hybrid would be expected to be more antigenic compared to MSQ because of the presence of the human R484 -I508 segment. Figure   2B shows that ELISA titers of most of the plasmas were increased using HM1 as the target antigen compared to MSQ. The difference between the HM1 and MSQ groups was statistically significant (p < 0.02, paired t test).
Additionally, in the plasmas from mice immunized with HSQ, there was a significant correlation between the reduction in antigenicity of HP9 compared to HSQ and the increase in antigenicity of HM1 compared to MSQ (Figure 3) . Thus, the degree to which individual mice developed an immune response to the R484 -I508 epitope could be detected similarly in both assay systems. This indicates that the reduced antigenicity of HP9 and the increased antigenicity of HM1 are not artifactual, for example, due to differences in antigen binding to microtiter plates. The hemophilia A mice in the HSQ, HSQ R484A/R489A and HSQ R484A/R489A/P492A treatment groups received six 10 µg/kg intravenous injections at 14 day intervals and a final injection of 25 µg/kg as described in Materials and Methods. Plasmas were obtained two weeks after the last injection and tested for inhibitory anti-fVIII antibodies using a modified Bethesda assay in which isologous antigen was added to human hemophilia A plasma (e.g., HSQ was added to human hemophilia A plasma to test plasmas from mice immunized with HSQ). Figure 4 shows the Bethesda titers for individual mice. The titers of two mice in each of the HSQ R484A/R489A/P492A and HSQ R484A/R489A group were less than 0.8 Bethesda units and are not plotted. The Bethesda titers were lower in the HSQ R484A/R489A/P492A group compared to the control HSQ group (p = 0.01, Mann-Whitney U test). In contrast, inhibitor levels in the HSQ R484A/R489A group were not significantly different from the control group. Plasmas from the HSQ and HSQ R484A/R489A/P492A groups also were tested for anti-fVIII antibodies by ELISA using immobilized Figure 5 ). The ELISA titers of the two mice in the HSQ R484A/R489A/P492A group that tested negative in the Bethesda assay were less than 50 and are not plotted. There was no significant difference between the groups.
Inhibitory antibody titers in hemophilia
Comparative hemostatic efficacy of HSQ and HSQ R484A/R489A/P492A
The hemostatic efficacy of HSQ R484A/R489A/P492A was measured in hemophilia A mice using a tail vein transection model 27 . Under the conditions used, tail vein transection is uniformly fatal within 24 h in untreated mice. The estimated dose of HSQ R484A/R489A/P492A that produces 50% survival (ED 50 ) was measured using the up-and-down method 28, 29 as described in Materials and Methods. In this method, a single subject is given a dose that is an a priori estimate of the ED 50 . If the subject survives, another subject is tested and the dose is decreased. If the subject dies, the dose is increased in the next subject, and so on, until a nominal sample size of six is reached. The results are shown in only.
Discussion
We tested the hypothesis that mutagenesis of an immunodominant fVIII B cell epitope can reduce the inhibitory antibody response to fVIII. The A2 epitope was selected for study because it contains known antigenic amino acids that can be mutated without loss of procoagulant function 15, 18 . Two BDD fVIII mutants containing mutations at R484A/R489A and R484A/R489A/P492A, respectively, were compared to BDD human fVIII in hemophilia A mice.
We used an immunogenicity model developed by Qian et al. in which fVIII is given intravenously to hemophilia A mice using a dosing schedule that mimics clinical use 31 . Mice received 10 µg/kg (~ 80 U/kg) fVIII every two weeks for six doses and a final dose of 25 µg/kg (~ 200 U/kg) two weeks later. These doses correspond to the high end of the clinical spectrum on a body weight basis. The high titer inhibitory antibody response that occurred was consistent with observations by other groups using similar dosing regimens [31] [32] [33] [34] .
The E16 knockout hemophilia A mice used in this study, along with the genetically similar, phenotypically indistinguishable E17 knockout mice, develop an immune response to human fVIII that requires CD4 + T cell help 31, 32, 34 and B7/CD28 and CD40/CD40L co-stimulation pathways 35 36-38 . IgG1, IgG2a and IgG2b anti-fVIII antibodies are produced, which indicates a combined Th1 and Th2 response 37 34,38,39 . FVIII -specific IFN- + 38 , IL-4 + 34 , and IL-10 + T cells 34, 38 have been identified in immunized mice, which also is consistent with a combined Th1 and Th2 response. In human hemophilia A, anti-fVIII antibodies are a mixture of IgG1, IgG2 and IgG4 antibodies [40] [41] [42] [43] , which also indicates a combined Th1 and Th2 response.
T cell proliferation assays using spleen cells from immunized hemophilia A mice in response to synthetic peptides that overlap the entire human fVIII sequence indicate that the A1, A2, A3, B, C1 and C2
domains all contain T cell epitopes 34 . Similar results have been obtained using peripheral blood mononuclear cells from hemophilia A patients with inhibitory antibodies to fVIII 44 . Thus, the immune response to fVIII in human and murine hemophilia A appears to be similar. However, for hemophilia A mice only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From to be a valid model for studying the immunogenicity of fVIII, it is necessary that they recognize the A2 R484 -I508 epitope. This was confirmed in the present study by evaluating the antigenic properties of hybrid human/porcine and human/murine fVIII molecules in hemophilia A mice that were immunized with human BDD fVIII. HP9, which is human except for insertion of porcine sequence within the R484 -I508 segment, was less antigenic than human BDD fVIII (Fig 2A) . In contrast, HM1, which is murine except for insertion of human sequence within the 484 -508 segment, was more antigenic than murine BDD fVIII (Fig 2B) . The underlying hypothesis in this study is that initial BCR -dependent antigen recognition and/or antigen presentation is a function of the structure of the antigen itself. This contrasts with the view that the entire surface of a protein is potentially immunogenic and that host regulatory mechanisms, especially T helper functions, direct the outcome of the antibody response 46 . This latter reasoning is based partly on the fact that it is possible to raise antibodies to nearly the entire surface of a protein, at least when small globular proteins are used as immunogens in the presence of strong adjuvants. Additionally, the vertebrate only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From immune system has evolved mechanisms to produce an almost unlimited antibody repertoire in any individual. However, if a distinction is made between possible epitopes and dominant epitopes, the hypothesis that a hierarchy of immunodominant epitopes exists that is a function of the intrinsic immunogen structure seems tenable. Conceivably, the co-evolution of immunoglobulin genes and pathogens led to a bias toward structures that antibodies recognize more easily.
In support of this hypothesis, the R484A/R489A/P492A mutant, but not the R484A/R489A mutant, produced lower inhibitory anti-fVIII antibodies in hemophilia A mice compared to the control group receiving human BDD fVIII. This suggests that P492 is particularly important in the immunogenicity of fVIII. An X-ray structure of the A2 domain is not available. However, a model of the fVIII A1 -A2 -A3 domains has been developed 47 by homology to the triplicated A domain structure of ceruloplasmin 48 . In the model, the R484 -I508 segment projects as a large loop between two -strands. The loop is surface-exposed and does not interact with the A1 or A3 domains, suggesting that it has significant conformational flexibility. Proline has less conformational freedom than any other amino acid residue because its side chain is fixed by a covalent bond to the main chain. Conceivably, the loss of structural constraints associated with the P492A mutation is associated with a decrease in the intrinsic immunogenicity of the R484 -I508 loop. Although it has been proposed that mobile antigenic sites are inherently more immunogenic than less mobile segments, this hypothesis has not been firmly established 49 .
Although our hypothesis is that the immunogenicity of fVIII can be reduced at the level of the BCR, we cannot exclude the possibility that the R484A/R489A/P492A mutant altered a T cell epitope. The relationship between B and T cell epitopes has been investigated in several antigenic systems. The B cell epitope of some antigens is protected from proteolytic degradation and MHC class II presentation by being bound to the BCR, leading to a bias against T -B cell epitope overlap 50 . However, there are examples in which B and T cell epitopes do overlap 51 . Additionally, in some cases, antibody binding to antigen can enhance the presentation of one T cell determinant while simultaneously suppressing the presentation of a different T cell determinant within the same antibody footprint 52 . Overlap of B and T cell epitopes was identified in a patient with mild hemophilia A that was produced by a R2150H missense mutation in the fVIII C1 domain 53 . The patient developed antibodies to wild-type fVIII, but not self-fVIII, indicating that the B cell only.
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The R484 -I508 region in fVIII can be subjected to extensive mutagenesis yet retain full procoagulant activity 18 . In the present study, the specific activity of the R484A/R489A/P492A mutant was not significantly different from BDD human fVIII (Materials and Methods). The R484 -I508 region also interacts with the low-density lipoprotein receptor related protein in mice and participates in the clearance of fVIII 54 . However, the in vivo clearance and hemostatic efficacy of the R484A/R489A/P492A mutant are indistinguishable from BDD human fVIII (Table 1 and Results). This indicates that residues in the R484 -I508 epitope that are involved in fVIII procoagulant activity and clearance differ from antigenically important residues. Alternatively, the R484 -I508 segment may not be involved in functionally important macromolecular interactions and antibodies to this region may be inhibitory due to steric hindrance.
Inhibitory antibodies to fVIII were measured using a modified Bethesda assay, which also detects anti-C2 and other inhibitory antibodies in addition to anti-A2 antibodies 13, 16 . Antibody neutralization assays indicate that human anti-A2 and anti-C2 antibodies contribute approximately equally to the overall inhibitor titer 13 . Our results in the murine system are consistent with this observation because mutagenesis of the A2 epitope resulted in only a partial reduction of the inhibitor titer. Combined mutagenesis of the A2 and C2 domains possibly could further reduce the immunogenicity of human fVIII.
In contrast to the Bethesda assay results, there was no significant difference between the R484A/R489A/P492A mutant and BDD human fVIII groups in anti-fVIII antibodies measured by ELISA, which detects both inhibitory and non-inhibitory antibodies (Fig. 5) . Non-inhibitory anti-fVIII antibodies have been identified in human hemophilia A patients 43 , although their relative contribution to the total antibody response is not known. The results of the present study suggest that the ELISA is insensitive to reduction in immunogenicity of the A2 inhibitor epitope because of the background due to non-inhibitory antibodies and inhibitory non-A2 antibodies.
The incidence of inhibitory antibody development to human BDD fVIII was 100% in the hemophilia A mice (Figure 4 ). In contrast, most patients with hemophilia A do not develop inhibitory antibodies, despite only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From repeated exposure to fVIII, suggesting that a state of immune tolerance develops. It is possible that lower doses of fVIII in the hemophilia A mouse model similarly would produce an immune group and a tolerant group. If so, it would be important to determine whether the R484A/R489A/P492A mutant reduces the incidence of inhibitory antibody development as a predictor of its potential clinical use as a low immunogenicity fVIII product.
Normal C57BL/6 mice mount a lower immune response to human fVIII than E16 hemophilia A mice, indicating that they are partially tolerant due to sequence similarity between human and murine fVIII 31 . E16
and E17 mice contain targeted disruptions in the region of the fVIII gene that encodes the A3 domain 20, 55 .
Both strains produce a circulating, non-functional polypeptide that includes the A2 domain 56 . However, the E16 hemophilia A mice are not tolerant to the A2 domain (Figures 2 and 3 ). This may be due to non-native folding of the truncated fVIII polypeptide chain, which prevents induction of tolerance. Alternatively, differences in amino acid sequences between human and murine A2 domain may be responsible for the µg/kg of HSQ, HSQ R484A/R489A/P492A or HSQ R484A/R489A at 14 day intervals, followed by a final injection of 25 µg/kg two weeks after the sixth dose. Blood samples were taken two weeks after the final injection and were tested for inhibitory anti-fVIII antibodies by a modified Bethesda assay using isologous antigen in human hemophilia A plasma as substrate as described in Materials and Methods. The horizontal lines represent the sample means. The statistical parameters of the samples (mean ± s.d.) were 670 ± 500, 320 ± 310, and 780 ± 570 for the HSQ, HSQ R484A/R489A/P492A, and HSQ R484A/R489A groups, respectively. only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Figure 5 . Anti-fVIII ELISA titers in hemophilia A mice immunized with HSQ and HSQ R484A/R489A/P492A. Plasmas from the HSQ and HSQ R484A/R489A/P492A groups described in Fig. 4 were tested for anti-fVIII antibodies by ELISA using plates coated with isologous antigen as described in only.
Materials and
